{
    "clinical_study": {
        "@rank": "73922", 
        "arm_group": {
            "arm_group_label": "NKTR-102", 
            "arm_group_type": "Experimental", 
            "description": "A single 90 minute IV infusion of 220 mg/m2 NKTR-102"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this research study is to evaluate the effect of NKTR-102 on the QT/QTc\n      interval in patients with advanced or metastatic solid tumors"
        }, 
        "brief_title": "A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Advanced Cancer", 
            "Metastatic Solid Tumors"
        ], 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is an open-label study that will assess the effect of NKTR- 102 on cardiac ventricular\n      repolarization, as characterized by QTcF (QT interval with Fridericia correction) interval\n      values, in patients with advanced or metastatic solid tumors following administration of a\n      single dose of NKTR-102."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Advanced or metastatic solid tumor refractory to standard therapy\n\n          -  Measurable or non-measurable disease\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n\n          -  Resolution of acute toxic effects of prior chemotherapy and other cancer treatments\n\n          -  Left ventricular ejection fraction (LVEF) \u226550% by echocardiogram\n\n          -  Adequate bone morrow and organ function\n\n          -  Stopped tobacco use for 4 weeks prior to day 1 and during the study\n\n          -  Agree to use adequate contraception\n\n        Exclusion Criteria:\n\n          -  Previous anti-cancer therapy for malignancy within 4 weeks (6 weeks for the\n             nitrosoureas or mitomycin C) before day 1\n\n          -  Treatment with antiarrythmic drugs and any medication known to cause QTc prolongation\n             within 4 weeks before screening and during the study\n\n          -  Prior extensive anthracycline exposure\n\n          -  Administration of cytochrome P450 CYP3A4 inducers and inhibitors within 4 weeks\n             before day 1 and during the study\n\n          -  Intake of grapefruit, grapefruit juice, Seville oranges, or other products containing\n             grapefruit or Seville oranges within 14 days prior to day 1 and during the study\n\n          -  History of serious cardiovascular disease\n\n          -  Abnormal systolic blood pressure, diastolic blood pressure and/or heart rate\n\n          -  History of additional risk factors for Torsade de Pointes\n\n          -  Prolonged QTcF at screening and day -1\n\n          -  Important abnormalities of the ECG that may interfere with the interpretation of QTc\n             interval changes at screening\n\n          -  Implantable pacemaker or automatic implantable cardioverter defibrillator\n\n          -  UGT1A1 genotype of TA 7 in both alleles (homozygous UGT1A1*28) or TA 8 in either one\n             or both alleles (hetero- or homozygous for UGT1A1*37)\n\n          -  Any major surgery within 4 weeks prior to day 1\n\n          -  Concurrent treatment with other anticancer therapy\n\n          -  Untreated central nervous system metastases\n\n          -  Chronic or acute GI disorders resulting in diarrhea\n\n          -  Pregnancy or lactation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01976143", 
            "org_study_id": "12-102-12"
        }, 
        "intervention": {
            "arm_group_label": "NKTR-102", 
            "intervention_name": "NKTR-102", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 1, 2014", 
        "location": [
            {
                "contact": {
                    "email": "fiermontep@cc.UCSF.edu", 
                    "last_name": "Paula Fiermonte", 
                    "phone": "415-885-7605"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "UCSF Helen Diller Family Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Pamela Munster, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Smitha.Krishnamurthi@UHhospitals.org", 
                    "last_name": "Smitha Krishnamurthi, MD", 
                    "phone": "216-844-5467"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "University Hospitals Case-Medical Center Seidman Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Smitha Krishnamurthi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study to Evaluate the Effect of Nktr-102 for Injection (Etirinotecan Pegol) on the QT/QTC Interval in Patients With Advanced or Metastatic Solid Tumors", 
        "overall_contact": {
            "last_name": "Charleen Jue", 
            "phone": "415-482-5300"
        }, 
        "overall_official": {
            "affiliation": "Nektar Therapeutics", 
            "last_name": "Charleen Jue", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "10 pre-dose and 18 post-dose ECG measurements to evaluate the effect of NKTR-102", 
            "measure": "QTcF interval values", 
            "safety_issue": "Yes", 
            "time_frame": "Day -1 through Day 42"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01976143"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "1 pre-dose and 18 post-dose blood samples to measure concentrations of NKTR-102 and its metabolites", 
            "measure": "Pharmacokinetics (PK) and ECG Parameters", 
            "safety_issue": "No", 
            "time_frame": "Day 1 through Day 42"
        }, 
        "source": "Nektar Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nektar Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}